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Background: In selected patients with chronic pancreatitis, extensive pancreatectomy can be effective
for the treatment of intractable pain. The resultant morbid diabetes can be ameliorated with islet
autotransplantation (IAT). Conventionally, islet infusion occurs intraoperatively after islet processing. A
percutaneous transhepatic route in the immediate postoperative period is an alternative approach.
Methods: A prospectively collected database of patients undergoing pancreatectomy with percutane-
ous IAT (P-IAT) was reviewed. Hospital billing data were obtained and median charges determined and
compared with estimated charges for an intraoperative infusion method of IAT (I-IAT).
Results: Thirty-six patients (28 women; median age 48 years) underwent pancreatectomy with P-IAT.
Median operative time was 232 min (range: 98–395 min) and median estimated blood loss was 500 cc
(range: 75–3000 cc). Median time from pancreatic resection to islet transplantation was 269 min (range:
145–361 min). A median of 208 248 IEq (2298 IEq/kg) were harvested. Median peak portal venous
pressure during islet infusion was 13 mmHg (range: 5–37 mmHg). Postoperative complications occurred
in 15 patients (42%) and included hepatic artery pseudoaneurysm and portal vein thrombosis; the latter
occurred in two patients with portal pressures during infusion > 30 mmHg. At a median follow-up of
10.7 months, eight patients (22%) were insulin-free. Median pertinent charges for P-IAT were US$36 318
and estimated median charges for I-IAT were US$56 440. Surgeon time freed by P-IAT facilitated an
additional 66 procedures, charges for which amounted to US$463 375.
Conclusions: Percutaneous transhepatic IAT is feasible and safe. Islet infusion in the immediate post-
operative period is cost-effective. Further follow-up is needed to assess longterm results.
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Introduction
Chronic pancreatitis is a devastating and debilitating disease when
marked by severe and intractable abdominal pain. Frontline man-
agement strategies for patients with this disease target medical and
endoscopic intervention. However, non-operative treatment is
ineffective in nearly 50% of patients and thus surgical therapy
represents an important option. Surgical strategies for the man-
agement of chronic pancreatitis fall broadly into three categories
comprising the resection of diseased tissue, the drainage of
obstructed ducts, and a combination of both of these. The cardi-
nal aims of pancreatic surgery are the preservation of pancreatic
function, the delivery of durable pain relief, and the avoidance of
major morbidity and mortality. For most patients, these goals can
be achieved with partial resection and bypass procedures.
However, when traditional surgical management fails and intrac-
table pain and nausea make life unbearable for selected patients,
This paper was presented at the American Hepato-Pancreato-Biliary Asso-
ciation 11th Annual Meeting, Miami, FL, USA.
DOI:10.1111/j.1477-2574.2011.00332.x HPB
HPB 2011, 13, 511–516 © 2011 International Hepato-Pancreato-Biliary Association
there are sound surgical principles which indicate that total pan-
createctomy can be an appropriate and successful therapeutic
intervention.
For many years, surgeons have avoided total pancreatectomy
in order to evade the resultant labile diabetes of the apancreatic
state. The loss of endogenous insulin production, as well as that
of the counter-regulatory hormones (glucagon, pancreatic
polypeptide), often results in a difficult form of diabetes char-
acterized by wide swings in blood glucose levels and an incon-
sistent response to therapeutic insulin. In addition, patients
develop hypoglycaemic unawareness, which heightens the mor-
bidity of this condition. Islet autotransplantation (IAT),
however, has engendered new enthusiasm for total pancreatec-
tomy because it represents a method of ameliorating this
brittle diabetes in the patient post-pancreatectomy. Moreover,
earlier total pancreatic resection has the potential to impede
the development of post-pancreatectomy neuropathic pain
syndromes.
Islet autotransplantation involves taking the pancreas immedi-
ately after resection and transporting it to a clean cell laboratory
for processing. In the laboratory, it undergoes a process of
mechanical and enzymatic digestion to separate the islets from the
remainder of the gland. This islet harvesting procedure takes
several hours to accomplish.
In most centres, the isolated islets are then returned to the
operating room (OR), where the patient has been waiting under
anaesthesia, for autotransplantation. The cells are infused by
gravity through a catheter placed into an immediate branch of the
portal vein. In our programme, however, we have chosen to end
the operation and move the patient to the intensive care unit
(ICU) for stabilization and to await the islet harvest. When the
islets are prepared, the patient is transported to the interventional
radiology suite (IR), where the portal vein is accessed percutane-
ously through the liver under fluoroscopic guidance (Fig. 1).
The islets are then infused into the liver. This approach is
modelled after a similar technique used for cadaveric islet
allotransplantation.
An evaluation of outcomes was undertaken in order to assess
the feasibility and safety of this novel approach to IAT. In addition,
cost modelling was performed to appraise the cost efficiency of
this method compared with that of the more common intraop-
erative infusion method.
Materials and methods
Islet harvest
The pancreas is prepared on the back table in the OR by perfu-
sion with cold balanced electrolyte solution. Non-pancreatic
tissue is separated and the main pancreatic duct is cannulated.
The pancreas is then transported on ice to the clean cell labora-
tory. There, the prepared pancreas is hand-injected through the
main pancreatic duct with Liberase HI and placed in a
temperature-controlled circuit and subjected to mechanical agi-
tation to allow optimal enzymatic activity. The progress of diges-
tion is periodically evaluated; when the islets are found to be
optimally separated, the circuit is cooled and diluted. The islets,
now largely separated from the exocrine and connective tissue,
Figure 1 Schematic diagram comparing percutaneous transhepatic islet autotransplantation with the more common method of intraopera-
tive islet autotransplantation. OR, operating room; ICU, intensive care unit; IR, interventional radiology suite
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are recovered and assessed. They are placed in albumin solution
with heparin (70 U per kg of patient weight) and antibiotic
(cefazolin, 1 g).
Islet autotransplantation
Percutaneous transhepatic access to the portal vein is obtained in
the IR suite under fluoroscopic guidance. A Seldinger technique is
utilized to place a 5-F catheter into the main portal vein below the
confluence. The islets are infused by gravity through the catheter.
Portal venous pressures are measured initially, at the midpoint of
transplant and at the completion of infusion. At the end of the
procedure, the intraparenchymal access catheter tract is ablated
with gel foam to obtain haemostasis.
Outcomes assessment
A prospectively collected database of patients who underwent
pancreatectomy with percutaneous IAT (P-IAT) between March
2009 and May 2010 was reviewed. Clinical parameters including
demographics, perioperative course and outpatient follow-up
data were assessed. Islet harvest and transplant information was
evaluated.
Hospital billing data were obtained and pertinent charges
were determined as a direct correlate to costs. Specifically, all
patient charges for the relevant patient encounters were itemized
and reviewed. All potential differential charges between a percu-
taneous transhepatic IAT approach and the more common
intraoperative IAT route were delineated. Time-dependent OR
and IR charges were identified and defined for the P-IAT
route and the median value for the 36 patients was
calculated. Surgeons’ professional fees were excluded from the
analysis.
A model for calculated expected charges based on time-
dependent OR charges was established. To validate this method,
the expected charges for percutaneous transhepatic islet infusion
were calculated. These were compared with the actual median
charges to the patient.
Expected charges for a hypothetical intraoperative infusion
case at our institution were estimated based on the collected
financial data. Per minute OR charges (including anaesthesia
charges) were utilized and an additional 240 min of OR time was
assumed to be required in the intraoperative infusion method
(I-IAT). This additional 240 min was calculated as follows:
the median islet harvest time (time from pancreas removal to
islet infusion) was 270 min; 60 min was subtracted from this
for anastomosis (choledochojejunostomy, gastrojejunostomy);
30 min was subtracted for closure time but then re-added
as closure occurred after islet infusion in the intraoperative
infusion group, and an additional 30 min was added for
islet infusion in the OR, thus bringing the total to 240 min
(Fig. 2).
Expected charges for the hypothetical case of I-IAT were then
calculated and compared with expected and real charges for
P-IAT.
To determine surgeon opportunity costs, surgeons’ professional
fees for other cases performed on the same days as islet transplant
cases were determined.
Figure 2 Schematic diagram demonstrating the additional 240 min of operating room time required for the intraoperative infusion of islet
autotransplantation. OR, operating room; ICU, intensive care unit; IR, interventional radiology suite
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Results
During the 14-month period of the study (March 2009 to May
2010), 36 patients underwent pancreatectomy with P-IAT.
Twenty-eight (78%) of the patients were women. Median patient
age was 48 years (range: 19–62 years) and median body mass
index was 27 kg/m2 (range: 17.4–37.9 kg/m2) (Table 1). The aeti-
ology of pancreatitis was sphincter of Oddi dysfunction (n = 16),
idiopathic (n = 9), pancreas divisum (n = 4), alcohol-related (n =
4) and familial (n = 3). Seven patients had diabetes preoperatively.
Twenty-one patients underwent total pancreatectomy and 15
underwent partial (completion) pancreatectomy. Median opera-
tive time was 232 min (range: 98–395 min); median estimated
blood loss was 500 cc (range: 75–3000 cc). Median time from
pancreatic resection to islet transplantation (islet harvest time)
was 269 min (range: 145–361 min). A median of 208 248 IEq
(2298 IEq/kg) were harvested (range: 3667–1 168 725 IEq).
Median time of islet infusion was 30 min (range: 18–57 min).
Median peak portal venous pressure during islet infusion was
13 mmHg (range: 5–37 mmHg). Median change in portal venous
pressure during transplant was 3 mmHg (range: 0–33 mmHg).
Postoperative complications occurred in 15 patients (42%)
(Table 2) and included requirements for two re-operations, one
for bleeding and one for persistent lactic acidosis. Minor compli-
cations included wound infection (n = 4), pneumonia (n = 4),
intra-abdominal abscess (n = 3), urinary tract infection (n = 3),
deep vein thrombosis (n = 2) and acute renal failure (n = 1). One
patient had the significant complication (>Clavien grade III) of
prolonged ventilation. Complications related specifically to IAT
included partial portal vein thrombosis (PVT), which occurred in
two patients, in both of whom portal venous pressures during
infusion rose to >30 mmHg. One patient was diagnosed during
her completion portal venogram after transplant, was treated with
systemic heparin i.v. and thrombosis resolved within 24 h without
clinical consequence. The other was diagnosed remotely,
3 months post-transplant, incidentally on computed tomography
(CT). She was treated with heparin and then warfarin, and throm-
bosis resolved. One patient had both a hepatic artery pseudoan-
eurysm and a hepatic abscess. Median postoperative length of stay
was 10 days (range: 5–33 days).
At a median follow-up of 10.7 months, eight patients (22%)
were insulin-free and an additional 10 (28%) had minimal insulin
requirements (<10 U insulin/day).
Median actual pertinent charges for the P-IAT method were
US$36 318, calculated as an expected charge of US$38 955. Esti-
mated median charges for hypothetical I-IAT were US$56 440
(Fig. 3). Freeing the OR for other procedures to be performed on
other patients by the operative surgeon was demonstrated to allow
an additional 66 procedures to be performed on the days of the 36
IAT procedures. These procedures collectively represented
US$463 375 in surgeons’ professional fees.
Discussion
Selected patients suffering intractable debilitating pain caused by
chronic pancreatitis may benefit from total pancreatectomy.
Patients with diffuse small duct pancreatitis, without a dilated
main pancreatic duct or an inflammatory mass, obtain subopti-
mal analgesic results from drainage1 or targeted resection proce-
dures, and thus total pancreatectomy potentially represents their
best option for surgical pain relief. After surgery for chronic pan-
creatitis, at least 15% of patients have persistent or recurrent pain,
regardless of the aetiology of pancreatitis, the procedure under-
taken, or the centre at which it is conducted.2–8 Salvage pancreate-
ctomy in selected cases, particularly in patients in whom disease
progression is a suspected mechanism for failure, can be an effec-
tive means of pain control.2,9 Patients with hereditary pancreatitis
who demonstrate progressive disease have a risk for pancreatic
cancer estimated to be 50 times greater than that of the
healthy population and thus are good candidates for total
pancreatectomy.10
Islet autotransplantation, pioneered at the University of Min-
nesota, has been performed at several centres with good
outcomes.11–17 The most common method of islet infusion
involves intraoperative infusion through a direct branch of the
Table 1 Demographics of patients undergoing pancreatectomy with
islet autotransplantation (n = 36)
Factors
Women, n 28
Median age, years 48
Median body mass index, kg/m2 27
Operating time, min, median (range) 232 (98–395)
Operations performed, n
Total pancreatectomy 21
Completion pancreatectomy 15
Median estimated blood loss, cc, median (range) 500 (75–3000)
Table 2 Complications in 15 of 36 patients undergoing pancreatec-
tomy with islet autotransplantation
Complication n
Re-operation 2
Wound infection 4
Intra-abdominal abscess 3
Pneumonia 4
Prolonged ventilation 1
Acute renal failure 1
Urinary tract infection 3
Deep vein thrombosis 2
Portal vein thrombosisa 2
Hepatic artery pseudoaneurysm 1
Hepatic abscess 1
aPortal vein thrombosis occurred in two patients with peak infusion
pressures >30 mmHg
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portal vein or superior mesenteric vein. There are clear advantages
to this approach. Exposure is already obtained through the course
of surgery and direct visualization of the operative field during the
systemic heparinization that accompanies islet infusion allows the
opportunity to ensure haemostasis. The disadvantage of this
approach is that the islet harvest takes several hours (a median of
269 min in this series), and the patient is maintained under ana-
esthesia in the OR during this time.
An alternative method of infusion involves accessing the portal
vein via a percutaneous transhepatic route for islet infusion in the
IR suite in the immediate postoperative period. The wait for islet
harvest is then spent in the ICU rather than the OR and thus this
method optimizes the efficient use of OR time, a finite resource.
The percutaneous transhepatic method has been utilized in
cadaveric islet allotransplantation with minimal morbidity and
acceptable short-term outcomes.18–20 This study shows similarly
acceptable results for IAT performed using this method. In our
series, we observed four occurrences in three of 36 patients (8%)
of procedure-specific complications.
The two cases of PVT were partial, incidentally noted and easily
treated without apparent negative clinical consequence. Portal
vein thrombosis is of significant concern as a potentially life-
threatening complication. The islets as prepared for autoinfusion
are not purified as they are for allotransplant, as the purification
process is time-consuming and lends itself to islet instability and
islet loss. The remaining exocrine cells in the preparation are a
source of tissue thromboplastin and thus are potentially throm-
bogenic. Elevated portal venous pressure during infusion has been
found to be a risk factor for PVT in islet allotransplantation.20 A
portal vein pressure of >30 mmHg occurred only in the two
patients who developed PVT in this study, supporting this condi-
tion as a risk factor. Measurement of portal venous pressure
during infusion seems prudent; in patients with pressures
>30 mmHg, the infusion should be stopped and the pressure
allowed to decrease prior to completion of the transplant. This
elevated pressure in most cases seems to be a phenomenon of
volume rather than occlusion as the pressure typically returns to a
normal level promptly.Anticoagulation is also routinely employed
to minimize the occurrence of thrombosis.
A hepatic artery pseudoaneurysm was incidentally discovered
in one patient on CT in the postoperative period. This was
managed with percutaneous embolization. The patient developed
some surrounding fluid near the pseudoaneurysm with a small
amount of air in it after the embolization, in the setting of fever
and leukocytosis. This abscess was drained percutaneously with
image guidance and the patient was treated with antibiotics.
Transplanted islet function as measured by the need for exog-
enous insulin was acceptable: 22% of patients were insulin-free. It
is important to note that seven of the patients required insulin
preoperatively. This percentage is lower than those reported by
some groups,11–13,15,16 but greater than those reported by others.14,17
Presumably the overall functional outcomes of the transplanted
islets are related not only to technique of isolation and transplant,
but also very closely to preoperative patient selection.
The method employed to estimate expected charges for a pro-
cedure was validated by using the formula to estimate the
expected charges for the percutaneous transhepatic method of
islet infusion. These estimated charges were comparable with the
actual charges made to patients. Using this model, the estimated
charges for an intraoperative infusion were notably higher than
Figure 3 Cost calculations for patients undergoing percutaneous islet autotransplantation compared with estimated charges for intraop-
erative islet autotransplantation. OR, operating room; IR, interventional radiology suite
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those for the percutaneous method as a result of the variance in
the utilization of OR time. In addition, the provision of surgeon
time to perform other procedures in other patients represented
significant charges.
Conclusions
Total pancreatectomy with IAT offers a promising intervention for
pain relief in a select group of patients with chronic pancreatitis.
A percutaneous transhepatic method of IAT is feasible and safe.
Acceptable islet function is achieved. According to our modelling,
this novel approach is cost-efficient when compared with the
more common intraoperative infusion route. Longterm outcomes
are needed to fully assess the role of total pancreatectomy with IAT
in the management of pain caused by chronic pancreatitis.
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